Filing Flows

Filing Flows › Insight Molecular Diagnostics (IMDX) › Next earnings date

Insight Molecular Diagnostics (IMDX) earnings on Nov 16, 2026: what to expect

Insight Molecular Diagnostics (IMDX) is expected to report earnings on Nov 16, 2026, in 8 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.22 (−$0.24 to −$0.20, 2 estimates) on revenue of $244K, against −$0.23 and $260K a year ago. It beat the EPS estimate in 50% of the quarters on record; Filing Flows' model gives it a 65% chance of beating next time.

Report dateNov 16, 2026
Days to go8
EPS estimate−$0.22
Revenue estimate$244K
Beat rate50%

What to watch

Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:

Insight Molecular Diagnostics: revenue lines, growth year over year, Q2 2026Insight Molecular Diagnostics: revenue lines, growth year over year, Q2 2026Revenue-54%Laboratory Services-56%Kitted Products-12%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.23 on revenue of $133K, against the analysts' −$0.22.

The last report

Insight Molecular Diagnostics reported revenue of $239K for the second quarter 2026 (-54% Y/Y), net loss $11.3M: Laboratory Services $218K, Kitted Products $21K. How it makes money → · Every quarter →

Insight Molecular Diagnostics: EPS against the estimate, last 4 reportsInsight Molecular Diagnostics: EPS against the estimate, last 4 reportsEstimateReported−$0.24−$0.23Nov 25−$0.24−$0.72Mar 26−$0.26−$0.12May 26−$0.23−$0.24Aug 26
Latest (Aug 26): Estimate −$0.23, Reported −$0.24.

Insight Molecular Diagnostics' latest quarter

Insight Molecular Diagnostics, Q2 2026: revenue $239K (-54% year over year), net loss $11.3M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.

Questions

When does IMDX report earnings?

Insight Molecular Diagnostics is expected to report on Nov 16, 2026.

What are analysts expecting from Insight Molecular Diagnostics?

EPS of −$0.22 and revenue of $244K for the quarter.

Does Insight Molecular Diagnostics usually beat earnings?

It beat the consensus EPS estimate in 50% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.